Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer

Chen Wei Chiang, Yun Shih Lin, Fu Ling Chang, Tsai Yu Lin, Keng Chang Tsai, Wei Chun Huang Fu, Yu Ching Lee

Research output: Contribution to journalArticlepeer-review


Studies have shown that the high expression of EphA4 in gastric cancer tissues may correlate with unfavorable clinical pathological characteristics. Therefore, EphA4 may be an effective target for treating gastric cancer in addition to HER-2/neu. In this study, generated scFv S3 can bind endogenous EphA4 of gastric cancer cells and has significant membrane staining. Additionally, scFv S3 binding to EphA4 inhibits the growth and migration of cancer cells and the growth induction that ephrinA1 generates in gastric cancer cells. We found that EphA4 molecules may degrade through antibody treatment of cells, and the increase in LAMP1 and LAMP2 indicates that lysosome is involved in the degradation. The scFv S3 administration leads to the signals pAKT, pERK, and pSTAT3 decrease in cancer cells. The xenograft model of HER-2/neu low expressing gastric cancer cell SNU-16 exhibits better therapeutic effects by scFv S3 than trastuzumab scFv. The scFv S3 administration in vivo can degrade EphA4 molecules in tumor tissues, decreasing Ki67 and increasing cleaved C3 molecule expression. Furthermore, we identified and validated that scFv S3 generates essential ionic bonding with R162 on EphA4. The antibody may provide effective treatment for patients with gastric cancer and abnormal activation or overexpression of EphA4 signaling.

Original languageEnglish
Pages (from-to)161-170
Number of pages10
JournalBiochemical and Biophysical Research Communications
Publication statusPublished - Nov 5 2023

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology


Dive into the research topics of 'Single-chain fragment antibody disrupting the EphA4 function as a therapeutic drug for gastric cancer'. Together they form a unique fingerprint.

Cite this